Femasys Completes $10.2 Million Series B Financing Round

ATLANTA, April 29, 2015 /PRNewswire/ -- Femasys Inc., a developer of innovative medical devices for the women's healthcare market has raised a $10.2 million financing round.  The investor group was led by Legacy Capital Partners and Mario Family Partners, the family offices of life sciences industry veterans John Adams, Jr. and Dr. Ernest Mario. Joining the Company's board of directors is Mr. Adams, former CEO of Adams Respiratory Therapeutics.  Salem Partners, a Los Angeles based investment bank focused on life sciences, advised the Company on the transaction and participated as a principal investor.

Femasys has developed a groundbreaking non-surgical female sterilization device (FemBloc™ Permanent Contraceptive System) that allows physicians to deliver exclusively in their office a biomaterial through a catheter based system to permanently block the fallopian tubes that substantially reduces patient risks and costs by eliminating the use of anesthesia and permanent implants.  The company has also expanded options for women with its two commercially available products for diagnosis of infertility (FemVue® Saline-Air device) and cervical cancer (FemCerv® Endocervical Sampler) that present significant advantages for the patient, physician and healthcare system.   

"We are pleased to have the support and confidence of this esteemed group of investors," said Kathy Lee-Sepsick, Femasys' President and CEO. "This round of funding will enable Femasys to invest in the people and programs necessary to achieve the Investigational Device Exemption (IDE) milestone for FemBloc and expand commercialization globally for our diagnostic products to allow women access to better options when it comes to managing their health needs."

"Femasys fills an important and significant gap in the women's healthcare continuum," said John Q. Adams, Jr., Legacy Capital Partners. "We believe that both physicians and patients will have great interest in the innovative new technologies and that we can provide value to the company through our highly experienced investor syndicate."

ABOUT FEMASYS INC. | www.femasys.com 
Femasys Inc., based in Atlanta, GA, is a privately held corporation committed to advancing women's healthcare worldwide by expanding options for women with innovative medical devices and next generation advancements providing significant clinical impact.  Additional information about Femasys and the Company's products can be found at www.femasys.com

ABOUT LEGACY CAPITAL PARTNERS
John Adams, Jr. was the former CEO of Adams Respiratory Therapeutics, developer of the Mucinex brands. Adams was sold to Reckitt Benckiser in 2008 for $2.3 billion.  Mr. Adams has been in the pharmaceutical industry for over 30 years and has made investments in a number of development-stage companies.  Legacy Capital Partners is based in Southlake, TX.

ABOUT MARIO FAMILY PARTNERS
Mario Family Partners is the private equity arm of Dr. Ernest Mario's family office.  Dr. Mario was the former CEO of Alza Corporation which was sold to Johnson & Johnson for $12 billion in 2001, the largest-ever M&A deal for J&J at the time.  He was previously CEO of Glaxo and currently sits on the boards of Boston Scientific Corporation and Celgene Corporation among others.

ABOUT SALEM PARTNERS LLC | www.salempartners.com 
Salem Partners is a boutique investment bank and wealth management firm based in Los Angeles that specializes in raising growth capital and executing M&A assignments for companies in the media, life sciences and industrial sectors.  Salem has a strong track record in life sciences, having raised substantially all of the private capital for Adams Respiratory Therapeutics, ZS Pharma, Inc. and Neos Therapeutics.

Femasys, FemBloc, FemVue and FemCerv are registered trademarks of Femasys Inc.  All rights reserved.

Media Contact:            
Jerry Fink
770-500-3910

Logo - http://photos.prnewswire.com/prnh/20110502/CL93858LOGO 

SOURCE Femasys Inc.

Related Links

http://www.femasys.com